This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by BRADWEJN, J.
Right arrow Articles by WHITAKER, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BRADWEJN, J.
Right arrow Articles by WHITAKER, T.
The British Journal of Psychiatry (2005) 187: 352-359
© 2005 The Royal College of Psychiatrists

Venlafaxine extended-release capsules in panic disorder

Flexible-dose, double-blind, placebo-controlled study

JACQUES BRADWEJN, MD

Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada

ANTTI AHOKAS, MD

Lääkärikeskus Mehiläinen, Helsinki, Finland

DAN J. STEIN, MD, PhD

University of Stellenbosch, CapeTown, South Africa

ELISEO SALINAS, MD and GERARD EMILIEN, PhD

Wyeth Research, Paris, France

TIMOTHY WHITAKER, MD

Wyeth Research, Collegeville, Pennsylvania, USA

Correspondence: Dr Jacques Bradwejn, University of Ottawa Institute of Mental Health Research, Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Ontario, Canada K1Z 7K4. Tel: +1-613-7226521, extension 6546; fax: +1-613-7982973; e-mail: jbradwej{at}rohcg.on.ca

Declaration of interest J.B. received funding for a clinical trial from Pfizer, and for consultation from GlaxoSmithKline, Wyeth Research and Servier. D.J.S. received research grants and/or consultancy honoraria from AstraZeneva, Eli-Lilly, GlaxoSmithKline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Solvay and Wyeth. E.S., G.E. and T.W. are employees of Wyeth.

Background Venlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder.

Aims To evaluate the efficacy, safety and tolerability of venlafaxine ER in treating panic disorder.

Method Adult out-patients (n=361) with panic disorder were randomly assigned to receive venlafaxine ER (75–225 mg/day) or placebo for up to 10 weeks in a double-blind study.

Results Venlafaxine ER was not associated with a greater proportion of patients free from full-symptom panic attacks at the final on-therapy evaluation, but was associated with lower mean panic attack frequency and a higher proportion free from limited-symptom panic attacks, higher response and remission rates, and improvements in anticipatory anxiety, fear and avoidance. Adverse events were comparable with those of the drug in depression and anxiety disorders.

Conclusions Venlafaxine ER seems to be effective and well tolerated in the short-term treatment of panic disorder.


Related articles in BJP:

Highlights of this issue
KIMBERLIE DEAN
BJP 2005 187: 301-a13. [Full Text]  



This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
J. Davidson, D. Baldwin, D. J. Stein, E. Kuper, I. Benattia, S. Ahmed, R. Pedersen, and J. Musgnung
Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release: A 6-Month Randomized Controlled Trial.
Arch Gen Psychiatry, October 1, 2006; 63(10): 1158 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
P. TYRER

The British Journal of Psychiatry, October 1, 2006; 189(4): 390 - 390.
[Full Text] [PDF]

Home page
 NEJMHome page
W. J. Katon
Clinical practice. Panic disorder.
N. Engl. J. Med., June 1, 2006; 354(22): 2360 - 2367.
[Full Text] [PDF]

Home page
 JWatch PsychiatryHome page
Venlafaxine Improves Panic Symptoms
Journal Watch Psychiatry, February 22, 2006; 2006(222): 12 - 12.
[Full Text]

Home page
 JWatch Women's HealthHome page
Venlafaxine Improves Panic Symptoms
Journal Watch Women's Health, November 22, 2005; 2005(1122): 12 - 12.
[Full Text]